Fibrodysplasia Ossificans Progressiva (FOP)

Informatie over Fibrodysplasia Ossificans Progressiva (FOP)

FOP is een uiterst zeldzame genetische ziekte¹ die botvorming buiten het skelet en in de weke delen veroorzaakt..^1,2 . Ipsen benut nieuwe werkingsmechanismen via de ontwikkeling van twee onderzoeksactieve stoffen om mensen met FOP mogelijk een innovatieve behandeling te bieden.

Baujat G, Choquet R, Boueé S, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017:12(1):123.
Kaplan FS, Shen Q, Lounev V, et al. Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). J Bone Miner Metab. 2008; 26(6):521–30.

ECTS-conferentie 2021 – Ipsen-symposium over FOP

Spotlight op Heterotopic Ossification (HO): betere diagnose en zorg voor patiënten met FOP

Ontdek meer

Materialen en Presentaties

april 24, 2025

EAU 2025 Highlights – RCC

Oncologie, Niercelcarcinoom, Videos, PDFs & Podcasts
Time: 1 minuut leestijd

Fibrodysplasia Ossificans Progressiva (FOP)

Informatie over Fibrodysplasia Ossificans Progressiva (FOP)

Materialen en Presentaties

EAU 2025 Highlights – RCC

EAU 2025 Highlights – Prostate Cancer

EAU 2025 Highlights – Bladder Cancer

ASCO GU 2025 Highlights – RCC

ASCO GU 2025 Highlights – Prostate Cancer

ASCO GU 2025 Highlights – Bladder Cancer

Understanding ALGS: Clinical presentation and symptoms

Understanding PFIC: Clinical presentation and Symptoms

Genetic Cholestasis: Pharmacological treatment options

Liver transplantation for patients with cholestatic liver diseases

Challenges in the diagnosis of adults with cholestatic liver disease

Genetic cholestasis: How to diagnose?

Filmpje voor patiënten over TNM classificatie van prostaatkanker

Primary Biliary Cholangitis (PBC): epidemiology, diagnostic challenges and a shifting treatment paradigm

Podcast – ACRO-talks – Episode 2: Leven met Acromegalie

Podcast – ACRO-talks – Episode 1: Acromegalie in de spotlights

ESMO 2024 highlights – RCC

ESMO 2024 highlights – prostaatkanker

ESMO 2024 highlights – blaaskanker

ESPGHAN 2024: PFIC through a different lens – How can you change the course of the disease?

NETtalks – Leven met NET: de stem van de patiënt

NETtalks Episode 7 – First Line Frequencies: walk the talk through NET Diagnosis and Treatment

NETtalks Episode 6 – Echoes of complexity: NET G3/NEC Treatment explored

NETtalks Episode 5 – mTOR Tales: Exploring its role in the NET treatment story

NETtalks Episode 4 – Hormonal Harmony: SSA therapy in focus

NETtalks Episode 3 – Cutting Edge Chronicles: NET Surgery insights

NETtalks Episode 2 – Radiant Waves: Exploring the Breakthroughs of PRRT Treatment in NET (part 2)

NETtalks Episode 1 – Radiant Waves: Exploring the Breakthroughs of PRRT Treatment in NET (part 1)

EAU 2024: Guidelines on Prostate Cancer

Key Messages -Adjuvant Treatment of RCC by dr. Van Damme (UCL Saint-Luc)

Omgaan met injectieangst van uw patiënten

Introduction to NET-talks

Podcast – Dr Jacinto: Goal setting in the treatment of spasticity

ASCO 2024 highlights – RCC

ASCO 2024 highlights – prostaatkanker

ASCO 2024 highlights – blaaskanker

Cross-border Vision on aRCC Data from ASCO 2024: Q&A Clinical Cases

Cross-border Vision on aRCC Data from ASCO 2024: Q&A 1L+ Systemic Treatment

Cross-border Vision on aRCC Data from ASCO 2024: Clinical Case: Systemic therapy post adjuvant pembrolizumab for RCC

Cross-border Vision on aRCC Data from ASCO 2024: Clinical Case: 1L Systemic Therapy in advanced pRCC by Dr. Koutsoukos, Department of Medical Oncology, Metropolitan Hospital, Athens, Greece

Cross-border Vision on aRCC Data from ASCO 2024: Second Line and Beyond Advanced RCC Management: 2024 Data by Prof. dr. Albiges, Department of Cancer Medicine, Gustave Roussy, France

Hormonal therapy in prostate cancer care

Precision medicine for prostate cancer (mCRPC)

Screening and early detection of prostate cancer

Radiotherapy highlights in prostate cancer

EAU 2024 highlights – RCC

EAU 2024 highlights – prostaatkanker

EAU 2024 highlights – blaaskanker

De Gevolgen – het aanvaarden van spasticiteit

CVA, wat is het?

Key Messages – Local Therapy in RCC Radiotherapy by prof. Berghen (UZ Leuven)

Behandeling met botulinetoxine type A bij kinderen met spastische cerebrale parese

Wat is er nieuw in de behandeling van urinaire incontinentie met detrusoroveractiviteit ?

Wat is er nieuw in de behandeling van spasticiteit ?

Behandeling van cervicale dystonie met botulinetoxine type A

2022 & ASCO GU’23 Highlights van prostaatkankerchirurgie – Prof. Dr. Steven Joniau

1L aRCC Treatment: IO-TKI by prof. Gennigens (CHU Liège)

Presentation – Local Therapy in RCC Radiotherapy by prof. Berghen (UZ Leuven)

Key Messages – Local Therapy in RCC Cytoreductive Nephrectomy by prof. Albersen (UZ Leuven)

Presentation – Local Therapy in RCC Cytoreductive Nephrectomy by prof. Albersen (UZ Leuven)

Key Messages -Adjuvant Treatment of RCC by dr. Seront (UCL Saint-Luc

Doelen stellen bij spastische parese

ASCO GU Symposium 2024 Highlights: RCC

ASCO GU Cancers Symposium 2024 Highlights: Prostate Cancer

Presentatie: ASCO GU Cancers Symposium 2024 Highlights: Bladder Cancer

Key Messages “Adverse Event Management of Systemic Therapy in aRCC Pneumonitis” by prof. Wauters (UZ Leuven)

Key Messages “Adverse Event Management of Systemic Therapy in aRCC Cardiotoxicity” by dr. Von Kemp (UZ Brussel)

Adverse Event Management of Systemic Therapy in aRCC: Pneumonitis by prof. Wauters (UZ Leuven)

Adverse Event Management of Systemic Therapy in aRCC: Cardiotoxicity by dr. Von Kemp (UZ Brussel)

Key messages Immunology in RCC for Dummies by prof. Aspeslagh (UZ Brussel)

1L aRCC Treatment: Brain Metastases by prof. Gennigens (CHU Liège)

2L+ aRCC Treatment by prof. Rottey (UZ Gent)

Key Messages “1L aRCC Treatment: IMDC Favourable Risk Patients & When Do I Stop IO Therapy?” by prof. Beuselinck (UZ Leuven)

1L aRCC Treatment: When Do I Stop IO Therapy? by prof. Beuselinck (UZ Leuven)

1L aRCC Treatment: Favourable IMDC Risk Patients by prof. Beuselinck (UZ Leuven)

Crosstalk predicts clinical benefit of immunotherapy in renal cell carcinoma by dr. Kinget (UZ Leuven)

FORX Project by dr. Verhaert (UZ Brussel)